Filtered By:
Drug: Temodar
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 1478 results found since Jan 2013.
Cocrystallization of lenvatinib and temozolomide to improve the performance in terms of stability, dissolution, and tabletability
CrystEngComm, 2023, Advance Article DOI: 10.1039/D3CE00473B, PaperZhi-Qing Wang, Xia-Lin Dai, Dai-Lin Gu, Chao Wu, Tong-Bu Lu, Xiang-Tian Long, Jia-Mei Chen Cocrystallization of two anti-melanoma drugs, lenvatinib and temozolomide, resulted in two drug –drug cocrystal solvates presenting improved performance in terms of stability, dissolution, and tabletability, which show great potential to be developed as a drug combination. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - CrystEngComm latest articles - July 7, 2023 Category: Chemistry Authors: Zhi-Qing Wang Source Type: research
Clinical decision-making based on 11C-methionine PET in recurrent Cushing's disease with equivocal MRI findings
CONCLUSIONS: MET-PET is extremely useful for confirming equivocal lesions on MRI in patients with recurrent CD and for deciding further treatment options. The authors propose a novel protocol based on MET-PET results for treating patients with relapsing CD in whom the recurrent tumors cannot be confirmed with MRI.PMID:37410630 | DOI:10.3171/2023.5.JNS23179
Source: Journal of Neurosurgery - July 6, 2023 Category: Neurosurgery Authors: Atsushi Ishida Koichiro Kaneko Ryogo Minamimoto Masatoshi Hotta Naoko Inoshita Koji Takano Shozo Yamada Source Type: research
Retraction statement: Ding, J., Wang, X., Gao, J. and Song, T. (2021), Silencing of cystatin SN abrogates cancer progression and stem cell properties in papillary thyroid carcinoma. FEBS Open Bio, 11: 2186-2197
FEBS Open Bio. 2023 Aug;13(8):1540. doi: 10.1002/2211-5463.13664. Epub 2023 Jul 6.ABSTRACThttps://doi.org/10.1002/2211-5463.13221 The above article, published online on 08 June 2021 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors, the Editor-in-Chief Miguel De la Rosa, FEBS Press, and John Wiley and Sons Ltd. The retraction has been agreed following an investigation into concerns raised by a third party, which revealed inappropriate duplications between this and articles that were either previously published or published later in the same year [1-9]. Thus, the editors c...
Source: Genetics and Molecular Research - July 6, 2023 Category: Genetics & Stem Cells Source Type: research
Clinical decision-making based on 11C-methionine PET in recurrent Cushing's disease with equivocal MRI findings
CONCLUSIONS: MET-PET is extremely useful for confirming equivocal lesions on MRI in patients with recurrent CD and for deciding further treatment options. The authors propose a novel protocol based on MET-PET results for treating patients with relapsing CD in whom the recurrent tumors cannot be confirmed with MRI.PMID:37410630 | DOI:10.3171/2023.5.JNS23179
Source: Journal of Neurosurgery - July 6, 2023 Category: Neurosurgery Authors: Atsushi Ishida Koichiro Kaneko Ryogo Minamimoto Masatoshi Hotta Naoko Inoshita Koji Takano Shozo Yamada Source Type: research
Retraction statement: Ding, J., Wang, X., Gao, J. and Song, T. (2021), Silencing of cystatin SN abrogates cancer progression and stem cell properties in papillary thyroid carcinoma. FEBS Open Bio, 11: 2186-2197
FEBS Open Bio. 2023 Aug;13(8):1540. doi: 10.1002/2211-5463.13664. Epub 2023 Jul 6.ABSTRACThttps://doi.org/10.1002/2211-5463.13221 The above article, published online on 08 June 2021 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors, the Editor-in-Chief Miguel De la Rosa, FEBS Press, and John Wiley and Sons Ltd. The retraction has been agreed following an investigation into concerns raised by a third party, which revealed inappropriate duplications between this and articles that were either previously published or published later in the same year [1-9]. Thus, the editors c...
Source: Genetics and Molecular Research - July 6, 2023 Category: Genetics & Stem Cells Source Type: research
Interferon- γ inducible protein 30 promotes the epithelial-mesenchymal transition-like phenotype and chemoresistance by activating EGFR/AKT/GSK3β/β-catenin pathway in glioma
CONCLUSION: The present study suggests that IFI30 is a regulator of the EMT-like phenotype and acts not only as a prognostic marker but also as a potential therapeutic target for temozolomide-resistant glioma.PMID:37408388 | DOI:10.1111/cns.14334
Source: CNS Neuroscience and Therapeutics - July 6, 2023 Category: Neuroscience Authors: Ying Chen Hui Xu Pei Yu Qing Wang Shenggang Li Fufu Ji Chunwang Wu Qing Lan Source Type: research
Retraction statement: Ding, J., Wang, X., Gao, J. and Song, T. (2021), Silencing of cystatin SN abrogates cancer progression and stem cell properties in papillary thyroid carcinoma. FEBS Open Bio, 11: 2186-2197
FEBS Open Bio. 2023 Aug;13(8):1540. doi: 10.1002/2211-5463.13664. Epub 2023 Jul 6.ABSTRACThttps://doi.org/10.1002/2211-5463.13221 The above article, published online on 08 June 2021 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors, the Editor-in-Chief Miguel De la Rosa, FEBS Press, and John Wiley and Sons Ltd. The retraction has been agreed following an investigation into concerns raised by a third party, which revealed inappropriate duplications between this and articles that were either previously published or published later in the same year [1-9]. Thus, the editors c...
Source: Genetics and Molecular Research - July 6, 2023 Category: Genetics & Stem Cells Source Type: research
Clinical decision-making based on 11C-methionine PET in recurrent Cushing's disease with equivocal MRI findings
CONCLUSIONS: MET-PET is extremely useful for confirming equivocal lesions on MRI in patients with recurrent CD and for deciding further treatment options. The authors propose a novel protocol based on MET-PET results for treating patients with relapsing CD in whom the recurrent tumors cannot be confirmed with MRI.PMID:37410630 | DOI:10.3171/2023.5.JNS23179
Source: Journal of Neurosurgery - July 6, 2023 Category: Neurosurgery Authors: Atsushi Ishida Koichiro Kaneko Ryogo Minamimoto Masatoshi Hotta Naoko Inoshita Koji Takano Shozo Yamada Source Type: research
Retraction statement: Ding, J., Wang, X., Gao, J. and Song, T. (2021), Silencing of cystatin SN abrogates cancer progression and stem cell properties in papillary thyroid carcinoma. FEBS Open Bio, 11: 2186-2197
FEBS Open Bio. 2023 Aug;13(8):1540. doi: 10.1002/2211-5463.13664. Epub 2023 Jul 6.ABSTRACThttps://doi.org/10.1002/2211-5463.13221 The above article, published online on 08 June 2021 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors, the Editor-in-Chief Miguel De la Rosa, FEBS Press, and John Wiley and Sons Ltd. The retraction has been agreed following an investigation into concerns raised by a third party, which revealed inappropriate duplications between this and articles that were either previously published or published later in the same year [1-9]. Thus, the editors c...
Source: Genetics and Molecular Research - July 6, 2023 Category: Genetics & Stem Cells Source Type: research
Clinical decision-making based on 11C-methionine PET in recurrent Cushing's disease with equivocal MRI findings
CONCLUSIONS: MET-PET is extremely useful for confirming equivocal lesions on MRI in patients with recurrent CD and for deciding further treatment options. The authors propose a novel protocol based on MET-PET results for treating patients with relapsing CD in whom the recurrent tumors cannot be confirmed with MRI.PMID:37410630 | DOI:10.3171/2023.5.JNS23179
Source: Journal of Neurosurgery - July 6, 2023 Category: Neurosurgery Authors: Atsushi Ishida Koichiro Kaneko Ryogo Minamimoto Masatoshi Hotta Naoko Inoshita Koji Takano Shozo Yamada Source Type: research
